A novel 125I-labeled daunorubicin derivative for radionuclide-based cancer therapy

« Previous Next »Nuclear Medicine and Biology
Volume 33, Issue 6 , Pages 773-783, August 2006

A novel ¹²⁵I-labeled daunorubicin derivative for radionuclide-based cancer therapy

Ludger M. Ickenstein
- Department of Physical and Analytical Chemistry, Uppsala University, P.O. Box 579, 75121 Uppsala, Sweden
Katarina Edwards
- Department of Physical and Analytical Chemistry, Uppsala University, P.O. Box 579, 75121 Uppsala, Sweden
Stefan Sjöberg
- Department of Biochemistry and Organic Chemistry, Uppsala University, P.O. Box 576, 75123 Uppsala, Sweden
Jörgen Carlsson
- Rudbeck Laboratory, Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, 75185 Uppsala, Sweden
Lars Gedda
- Rudbeck Laboratory, Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, 75185 Uppsala, Sweden
- Rudbeck Laboratory, Division of Experimental Urology, Department of Surgery, Uppsala University, 75185 Uppsala, Sweden
- Corresponding author. Rudbeck Laboratory, Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, 75185 Uppsala, Sweden. Tel.: +46 18 4713431; fax: +46 18 4713432.